Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | QDPR | P09417 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578563 | 0.83 | HTR2C (0.50) | MAPTKDM1AHTR2CQDPRSIGMAR1 | |
| SCHEMBL4789908 | 0.83 | PTGS1 (0.34) | MAPTPRCPQDPRSIGMAR1KHK | |
| SCHEMBL4790395 | 0.83 | SIGMAR1 (0.50) | PRCPHTR2CSIGMAR1 | |
| SCHEMBL7369173 | 0.81 | NISCH (0.35) | NISCHMAPTPRCPHTR2CQDPR | |
| SCHEMBL4790187 | 0.79 | CHRNB2 (0.38) | NISCHMAPT | |
| SCHEMBL5120222 | 0.79 | HTR2C (0.38) | NISCHKDM1AHTR2C | |
| SCHEMBL4790258 | 0.79 | NISCH (0.46) | NISCHHTR2CACHE | |
| SCHEMBL7747172 | 0.75 | QDPR (0.53) | MAPTQDPR | |
| SCHEMBL24521821 | 0.72 | NISCH (0.39) | NISCHMAPTACHETDP1 | |
| Trifluoroacetic Acid SCHEMBL16422651 | 0.72 | KDM1A (0.43) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | NISCH 3223/4885MAPT 2861/4885PRCP 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.